How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

685 results for

Pulmonary Hypertension in Sickle Cell Anemia


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

341. Epidemiology and Pathophysiological Mechanisms of HTAP in SS and SC Children in Martinique and Guadeloupe.

a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Centre Hospitalier Universitaire de Pointe-a-Pitre: Pulmonary arterial hypertension SCD Epidemiology Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn (...) Update Posted : December 11, 2017 Sponsor: Centre Hospitalier Universitaire de Pointe-a-Pitre Information provided by (Responsible Party): Centre Hospitalier Universitaire de Pointe-a-Pitre Study Details Study Description Go to Brief Summary: pulmonary arterial hypertension (PAH) has been reported with a prevalence of approximately 30% in adult sickle cell disease (SCD) patients, with an increased mortality in SCD patients with PAH, compared with those without PAH. The identification of several

2017 Clinical Trials

342. Mylan Insulin Glargine Study

of other severe psychiatric diseases (manic depressive psychosis [MDP], schizophrenia), which in the opinion of the investigator precludes the subject from participating in the study (recorded while collecting subject history). History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, sickle cell anemia, etc.). Subjects using the following in the 3 months prior to screening: Insulin pump therapy Any anti-diabetic drugs other than (...) hypertension by Joint National Committee VII (even if therapy is ongoing, blood pressure ≥160 mm Hg systolic or ≥100 mm Hg diastolic). Uncontrolled hyperlipidemia (even if therapy is ongoing, LDL >160 mg/dL or triglycerides >500 mg/dL). Uncontrolled hyperthyroidism or hypothyroidism (subjects can be included if these conditions are controlled with thyroid hormones or anti-thyroid drugs). Impaired hepatic function (alanine transaminase [ALT] or aspartate transaminase [AST] value >2 times the upper limit

2017 Clinical Trials

343. COOL-AMI EU Pivotal Trial

has a known history of bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, or will refuse blood transfusions. The patient has a height of <1.5 meters (4 feet 11 inches). The patient has a known hypersensitivity or contraindication to buspirone hydrochloride or Pethidine (Meperidine) and/or has been treated with a monoamine oxidase inhibitor in the past 14 days. Patient has a known history of severe hepatic or renal impairment, untreated hypothyroidism, Addison's disease, benign (...) with ST-segment elevation of >= 0.2 mV in two or more anterior contiguous precordial leads. The patient is eligible for PCI. The patient is willing to provide written informed consent to participate in this clinical trial. Exclusion Criteria: The patient has had a previous Myocardial Infarction. The patient is experiencing cardiogenic shock (systolic blood pressure [SBP] <80 mmHg and non-responsive to fluids, or SBP <100 mmHg with vasopressors, or requirement for an intra-aortic balloon pump [IABP

2017 Clinical Trials

344. Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia

for the treatment of anemia. This study, PHI112844, will be the first administration of compound 1278863A to investigate the pharmacodynamics/efficacy, safety, tolerability, and pharmacokinetics of repeat oral doses in anemic pre-dialysis patients with moderate or severe renal impairment and in hemodialysis-dependent patients. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 107 participants Allocation: Randomized Intervention Model: Parallel (...) , 29, 36, 57 ] Safety Labs (Hematology) [ Time Frame: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57 ] Safety Labs (Urinalysis) [ Time Frame: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57 ] Vital Signs (blood pressure and heart rate) [ Time Frame: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57 ] ECG [ Time Frame: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57 ] Secondary Outcome Measures : AUC (0-∞), Cmax, tmax, t½ [ Time Frame: Day 1, 15, 22 ] Actual values and change from baseline for erythropoietin, absolute

2010 Clinical Trials

345. Childhood Cancer Genomics (PDQ®): Health Professional Version

% of cases of B-ALL, but very rarely in cases of T-cell ALL.[ ] Hyperdiploidy can be evaluated by measuring the DNA content of cells (DNA index) or by karyotyping. In cases with a normal karyotype or in which standard cytogenetic analysis was unsuccessful, interphase fluorescence in situ hybridization (FISH) may detect hidden hyperdiploidy. High hyperdiploidy generally occurs in cases with clinically favorable prognostic factors (patients aged 1 to <10 years with a low white blood cell [WBC] count (...) chromosomes (n = 46). Low-hypodiploid: 33 to 39 chromosomes (n = 26). High-hypodiploid: 40 to 43 chromosomes (n = 13). Near-diploid: 44 chromosomes (n = 54). Most patients with hypodiploidy are in the near-haploid and low-hypodiploid groups, and both of these groups have an elevated risk of treatment failure compared with nonhypodiploid cases.[ , ] Patients with fewer than 44 chromosomes have a worse outcome than do patients with 44 or 45 chromosomes in their leukemic cells.[ ] A number of studies have

2016 PDQ - NCI's Comprehensive Cancer Database

346. Hyphema

Related Chapters II. Definition Bleeding in the anterior chamber of the eye III. Causes Blunt (most common) Injury to the iris root (outer edge of the iris where it meets the ) Subsequent bleeding arises from the iris blood vessels Post-surgical Spontaneous bleeding without injury history IV. Exam Determine amount of bleeding (height of Hyphema) Evaluate for High pressure suggests blood clogging the trabecular drainage V. Labs Sickle Cell preparation in non-caucasian patients Perform even in tic cases (...) (AMICAR) Oupatient management 1% single dose Results in complete paralysis of the iris muscle for 2 weeks Other s do not completely paralyze the iris and require frequent re-dosing agent (if increased) (e.g. ) - Preferred first-line agent ( , ) ( , ) IX. Management: Sickle Cell Anemia Requires emergent management Risk of Eye vaso- Risk of acute angle closure Risk of Admit all patients with Hyphema (even small Hyphemas) Raise head of bed Consult ophthalmology Agents that may be used in and Hyphema s

2018 FP Notebook

347. Late Effects of Treatment for Childhood Cancer (PDQ®): Health Professional Version

: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 152 (7): 444-55; W144-54, 2010. [ ] [ ] Jones DP, Spunt SL, Green D, et al.: Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatr Blood Cancer 51 (6): 724-31, 2008. [ ] [ ] Liles A, Blatt J, Morris D, et al.: Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary (...) Radiation therapy: Total dose, fraction size, organ or tissue volume, type of machine energy. Chemotherapy: Agent type, dose-intensity, cumulative dose, schedule. Surgery: Technique, site. Hematopoietic cell transplantation. Use of combined modality therapy. Blood product transfusion. Management of chronic graft-versus-host disease. Host-related factors Sex. Genetic predisposition. Premorbid health state. Developmental status. Age at diagnosis. Time from diagnosis/therapy. Inherent tissue sensitivities

2016 PDQ - NCI's Comprehensive Cancer Database

348. Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®): Health Professional Version

. Table 1. Syndromes and Conditions Associated With Wilms Tumor a Syndrome/Condition Gene Overgrowth Phenotype Non-Overgrowth Phenotype High Risk of Wilms Tumor (>20%) WAGR syndrome WT1 deletion X Denys-Drash syndrome WT1 missense mutation X Perlman syndrome DIS3L2 mutation X Fanconi anemia with biallelic mutations in BRCA2 ( FANCD1 ) or PALB2 ( FANCN ) BRCA2 , PALB2 X Premature chromatid separation/mosaic variegated aneuploidy Biallelic BUB1B or TRIP13 mutation X Moderate Risk of Wilms Tumor (5%–20 (...) and nephroblastomatosis, islet cell hypertrophy, multiple congenital anomalies, and mental retardation. Survivors have a high risk of developing Wilms tumor (75%).[ ] Germline inactivating mutations in DIS3L2 on chromosome 2q37 are associated with Perlman syndrome. Preliminary data suggest that DIS3L2 plays a role in normal kidney development and in a subset of sporadic Wilms tumor cases.[ ] Simpson-Golabi-Behmel syndrome. Simpson-Golabi-Behmel syndrome is characterized by macroglossia, macrosomia, renal and skeletal

2016 PDQ - NCI's Comprehensive Cancer Database

349. Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation

respiratory tract, also Table4 Cardiac and non-cardiac conditions that can mimic non-ST-elevation acute coronary syndomes Cardiac Pulmonary Haematological Vascular Gastro-intestinal Orthopaedic/ infectious Myocarditis Pulmonary embolism Sickle cell crisis Aortic dissection Oesophageal spasm Cervical discopathy Pericarditis Pulmonary infarction Anaemia Aortic aneurysm Oesophagitis Rib fracture Cardiomyopathy Pneumonia Pleuritis Cerebrovascular disease Peptic ulcer Muscle injury/ in?ammation Valvular (...) ), or coronary bypass graft (CABG) surgery], also raises the likelihood of NSTE-ACS. 3.2 Diagnostic tools 3.2.1 Physical examination The physical examination is frequently normal. Signs of heart failure or haemodynamic instability must prompt the physician to expe- dite diagnosis and treatment. An important goal of the physical examination is to exclude non-cardiac causes of chest pain and non-ischaemic cardiac disorders (e.g. pulmonary embolism, aortic dissection, pericarditis, valvular heart disease

2011 European Society of Cardiology

350. Cardiovascular Diseases during Pregnancy

Association aPTT activated partial thromboplastin time ARB angiotensin receptor blocker AS aortic stenosis ASD atrial septal defect AV atrioventricular AVSD atrioventricular septal defect BMI body mass index BNP B-type natriuretic peptide BP blood pressure CDC Centers for Disease Control CHADS congestive heart failure, hypertension, age (.75 years), diabetes, stroke CI con?dence interval CO cardiac output CoA coarction of the aorta CT computed tomography CVD cardiovascular disease DBP diastolic blood (...) ?ow tract obstruction MRI magnetic resonance imaging MS mitral stenosis NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association OAC oral anticoagulant PAH pulmonary arterial hypertension PAP pulmonary artery pressure PCI percutaneous coronary intervention PPCM peripartum cardiomyopathy PS pulmonary valve stenosis RV right ventricular SBP systolic blood pressure SVT supraventricular tachycardia TGA complete transposition of the great arteries TR tricuspid regurgitation

2011 European Society of Cardiology

351. Statement on pregnancy and travel

of toxemia, hypertension, or diabetes with any pregnancy / Antécédents de toxémie, d’hypertension artérielle ou de diabète au cours d’une grossesse (passée ou présente) • Primigravida at 35 years of age and older, or 15 years of age and younger / Primigeste de 35 ans et plus ou de 15 ans et moins • History of thromboembolic disease / Antécédents de maladie thrombo- embolique • Pulmonary hypertension / Hypertension artérielle pulmonaire • Severe asthma or other chronic lung disease / Asthme grave ou autre (...) maladie pulmonaire chronique • Valvular heart disease (if NYHA class III or IV heart failure) / Valvulopathie cardiaque (en présence d’une insuffisance cardiaque de classe III ou IV selon la New Y ork Heart Association [NYHA]) • Cardiomyopathy / Cardiomyopathie • Hypertension / Hypertension • Diabetes / Diabète • Renal insufficiency / Insuffisance rénale • Severe anemia or hemoglobinopathy / Anémie sévère ou hémoglobinopathie grave • Chronic organ system dysfunction re- quiring frequent medical

2010 CPG Infobase

352. Clinical Practice Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty

and/or mechanical compressive devices for the prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty, and who are not at elevated risk beyond that of the surgery itself for venous thromboembolism or bleeding. Grade of Recommendation: Moderate Description: Evidence from two or more “Moderate” strength studies with consistent findings, or evidence from a single “High” quality study for recommending for or against the intervention. A Moderate recommendation means (...) role. 9. We suggest the use of neuraxial (such as intrathecal, epidural, and spinal) anesthesia for patients undergoing elective hip or knee arthroplasty to help limit blood loss, even though evidence suggests that neuraxial anesthesia does not affect the occurrence of venous thromboembolic disease. Grade of Recommendation: Moderate Description: Evidence from two or more “Moderate” strength studies with consistent findings, or evidence from a single “High” quality study for recommending

2011 American Academy of Orthopaedic Surgeons

353. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease Full Text available with Trip Pro

and Beyond: A Presidential Advisory From the AHA ( ) AHA 2011 ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; ATP III, Adult Treatment Panel 3; JNC VII, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NHLBI, National Heart, Lung and Blood Institute; and SCAI, Society for Cardiovascular Angiography and Interventions. Patients with known IHD who were previously asymptomatic or whose (...) Modification: Recommendations. . . . . . . . . . . . . . . . .e395 Lipid Management. . . . . . . . . .e395 Blood Pressure Management. . .e397 Diabetes Management. . . . . . . .e398 Physical Activity. . . . . . . . . . . .e399 Weight Management. . . . . . . . .e400 Smoking Cessation Counseling. . . . . . . . . . . . . . . .e401 Management of Psychological Factors. . . . . . . .e401 Alcohol Consumption. . . . . . . .e402

2011 American Heart Association

354. Polysomnography for Sleep-Disordered Breathing Prior to Tonsillectomy in Children

weight (BMI 5th to 80%) because of upper airway narrowing caused by hypertrophy of the tongue, tonsils, adenoids, and mucous membranes. This narrowing is worsened by a physiological decrease in tone of the supporting muscles of the pharynx and increased airway resistance. 46 Sickle cell anemia is an autosomal recessive disorder of hemoglobin that alters the properties of red blood cells and is associated with varying degrees of anemia. 47 Strokes, tran- sient ischemic attacks, and seizures are common (...) the scientific evidence for a particular topic. 26 Making recommendations about health practices involves value judgments based on the desirability of various outcomes *High-risk populations include children with obesity, neuromuscular or cra- niofacial disorders, Down syndrome, mucopolysaccharidoses, or sickle cell disease.Roland et al S5 associated with management options. Values applied by the guideline panel sought to minimize harm and diminish unnec- essary and inappropriate therapy. A major goal

2011 American Academy of Otolaryngology - Head and Neck Surgery

355. Nivestim - filgrastim

. The process starts CHMP assessment report EMA/262762/2010 Page 6/48 by thawing one ampoule of the E. coli working cell bank, which is propagated to the biosynthesis step performed in bioreactor. Following completion of fermentation, the biomass is separated from the fermentation broth by flow-through centrifuge and used for release of inclusion bodies by homogenization in high pressure homogenizer. The wet paste of filgrastim inclusion bodies is packed as portions in containers with closure and following (...) ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. o The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. o Filgrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). o In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute

2010 European Medicines Agency - EPARs

356. Tepadina - thiotepa

toxicity and the lack of dose limiting extra-medullary toxicity of thiotepa. The compound is frequently given in combination with cyclophosphamide and busulfan or cyclophosphamide and carboplatin, as well as in other combinations of high-dose chemotherapy regimens. The use of thiotepa at high dosage as part of conditioning treatments prior to haematopoietic progenitor cell transplantation dates back to the late 1980s. In this context, thiotepa has been used in patients with a wide variety of disorders (...) , from leukaemia to solid tumours including CNS tumours, as it crosses the blood-brain-barrier and reaches the same concentration in the cerebrospinal fluid as in plasma, and from thalassemia to autoimmune disorders. Orphan Drug Designation was granted on 29 January 2007 by the European Commission for Tepadina in Conditioning treatment prior to haematopoietic progenitor cell transplantation (EU/3/06/424), based on the prevalence of the condition estimated to be in the range of 0.5 per 10,000

2010 European Medicines Agency - EPARs

357. Maternity Care Pathway

-pregnant weight (BMI of 19 – 27) and risks associated with • underweight, overweight and obesity 11,12 Physical activity • 13 Contraception choices that meet timing of desired pregnancy • Genetic counselling/testing as appropriate (such as • Ashkenazi Jewish Panel, Thalassemia, Sickle Cell Anemia) 14 Use of medications and supplements* • Lifestyle: including smoking cessation, alcohol consumption, substance use and Fetal Alcohol Spectrum • Disorder (FASD) prevention* History of communicable disease (...) vaccination for prevention in subsequent pregnancy guiJOGC203CPG0802.pdf Hepatitis C testing Recommend screening to women with risk factors: injection drug use (even once) • hemodialysis • persistent elevated AST • receipt of blood products or • organs before 1992 or clotting factors before 1988 exposure to blood of high-risk • individual prison inmates • HIV positive • tattoos not carried out in • properly regulated

2010 British Columbia Perinatal Health Program

358. A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

has received relugolix (including placebo) in a previous clinical study. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress. The participant has a previous or current history of blood disorders (eg, thalassemia, sickle cells anemia, folic-acid deficiency, and coagulopathy), excluding (latent) iron-deficiency anemia (...) , or within 1 month after the end of the study. The participant has a previous or current history of osteoporosis, osteopenia, or other metabolic bone diseases. The participant has clinically significant cardiovascular disease (eg, myocardial infarction or unstable angina pectoris within 24 weeks prior to VISIT 1) or uncontrollable hypertension (eg, resting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg at Screening and Run-in). The participant is inappropriate for participation

2016 Clinical Trials

359. Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction

) or vasospastic disorders (such as Raynaud's or thromboangitis obliterans. The patient has a known hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast [agents], which cannot be adequately pre-medicated. The patient has a known history of bleeding diathesis, coagulopathy, cryoglobulinemia or sickle cell anemia, or will refuse blood transfusion. The patient is < 1.5 m (4 feet 11 inches) tall. The patient has a known hypersensitivity to buspirone hydrochloride or meperidine (...) to provide a secondary measure of cell injury Composite of adverse events [ Time Frame: 30 days after STEMI ] Composite of adverse events, defined as: All-cause mortality Recurrent AMI Need for revascularization of the target vessel Cerebral vascular accident Cardiogenic shock Pulmonary embolism Ventricular fibrillation Vascular complications requiring surgery Bleeding requiring transfusion of 2 or more units of red blood cell concentrate Device complications [ Time Frame: 30 days after STEMI

2016 Clinical Trials

360. Lorcaserin Intra Venous Cocaine Effects

with aspartate transaminase or Alaine aminotransferase > 40 IU/L). History of priapism or conditions that would predispose to priapism (sickle cell anemia, multiple myeloma, leukemia, Peyronie's disease, or other anatomical deformation of the penis). Currently being treated for erectile dysfunction. Has an unstable medical condition, which, in the judgment of investigators, would make participation hazardous, such as AIDS or active TB. If female, is pregnant or lactating (nursing), not practicing adequate (...) laboratory results that demonstrate no contraindication to participation. Exclusion Criteria: Has a history of a medical adverse reaction to cocaine or other psycho stimulants, including loss of consciousness, chest pain, cardiac ischemia, or seizure. Has any current Axis I psychiatric disorder other than drug abuse or dependence. Meets DSM-IV-TR criteria for dependence on opiates, benzodiazepines, alcohol, or other sedative-hypnotics. Has received opiate-substitution therapy within two months prior

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>